CL
CLDX.US Celldex Therapeutics Inc
- Market cap
- USD 2.26B
- P/E
- -
- P/B
- 3.45x
- ROE
- -46.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CLDX.US undervalued?
Graham numberThe Graham number of Celldex Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Celldex Therapeutics Inc fundamental analysis
No fundamental analysis for Celldex Therapeutics Inc yet.
Celldex Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT recep…
Full company profileCelldex Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Celldex Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.79M | 12.7M | 9.54M | 3.57M | 7.42M | 4.65M | 2.36M | 6.88M | 7.02M | 1.50M | 49.3K |
| Gross Profit | -95.2M | -83.4M | -56.9M | -39.1M | -35.1M | -48.7M | -79.9M | -111M | -157M | 1.50M | -111M |
| Operating Income | -133M | -122M | -156M | -55.0M | -63.4M | -71.2M | -115M | -155M | -195M | -287M | -330M |
| EBITDA | -124M | -104M | -72.6M | -49.7M | -45.6M | -66.1M | -104M | -139M | -155M | -255M | -300M |
| Net Income | -129M | -93.0M | -151M | -50.9M | -59.8M | -70.5M | -112M | -141M | -158M | -259M | -304M |
| EPS | -19 | -11 | -14 | -3.51 | -2.02 | -1.64 | -2.40 | -2.92 | -2.45 | -3.89 | -3.87 |
| Balance Sheet | |||||||||||
| Total Assets | 383M | 316M | 156M | 123M | 236M | 445M | 353M | 466M | 792M | 583M | 722M |
| Total Liabilities | 118M | 79.3M | 31.7M | 28.9M | 26.5M | 25.2M | 26.5M | 36.5M | 45.3M | 55.8M | 72.1M |
| Shareholders' Equity | 265M | 236M | 124M | 94.0M | 209M | 419M | 326M | 429M | 747M | 527M | 649M |
| Cash & Short-term Investments | 190M | 139M | 94.0M | 64.2M | 194M | 408M | 305M | 422M | 725M | 519M | 650M |
| Total Debt | - | 6.57M | 4.53M | 3.66M | 3.48M | 3.04M | 4.03M | 2.54M | 3.81M | 2.34M | 9.87M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -113M | -99.9M | -75.2M | -46.4M | -40.4M | -60.9M | -104M | -107M | -158M | -211M | -251M |
| Capital Expenditure | 2.75M | 1.79M | 813K | 731K | 1.55M | 1.25M | 1.83M | 1.82M | 1.92M | 2.71M | 8.65M |
| Free Cash Flow | -116M | -102M | -76.0M | -47.1M | -42.0M | -62.2M | -106M | -109M | -160M | -214M | -259M |
| Ratios | |||||||||||
| ROE | -48.4% | -39.4% | -121.9% | -54.1% | -28.6% | -16.8% | -34.4% | -33.0% | -21.1% | -49.1% | -46.8% |
| ROA | -33.5% | -29.5% | -97.0% | -41.4% | -25.3% | -15.9% | -31.8% | -30.4% | -19.9% | -44.4% | -42.1% |
| Net Profit Margin | -1,894.0% | -730.1% | -1,585.1% | -1,424.0% | -805.9% | -1,516.0% | -4,765.6% | -2,054.8% | -2,248.8% | -17,253.3% | -615,527.1% |
| Debt to Equity | - | 0.03x | 0.04x | 0.04x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Celldex Therapeutics Inc dividends
Celldex Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Feb 11, 2019.
Who owns Celldex Therapeutics Inc
- Insiders 0.27%
- Institutions 99.73%
- Public & others 0.00%
- Shares outstanding 78.5M
- Free float 73.0M
Top funds holding CLDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Health Care Inv | 5.04M | 6.42% | +17.74% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.51M | 3.19% | +0.46% | Sep 2026 |
| iShares Russell 2000 ETF | 1.98M | 2.52% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.72M | 2.19% | +2.69% | Oct 2026 |
| Vanguard Explorer Inv | 1.46M | 1.85% | +0.54% | Sep 2026 |
| T. Rowe Price New Horizons | 1.07M | 1.36% | -11.03% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 1.04M | 1.32% | 0.00% | Jun 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 971K | 1.24% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 856K | 1.09% | +0.13% | Aug 2026 |
| Fidelity Stock Selector Small Cap | 855K | 1.09% | 0.00% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 803K | 1.02% | +34.69% | Sep 2026 |
| American Century Small Cap Growth Inv | 793K | 1.01% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 779K | 0.99% | +87.82% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 651K | 0.83% | 0.00% | Sep 2026 |
| Federated Hermes Kaufmann R | 641K | 0.82% | +112.39% | Sep 2026 |
| Pictet-Biotech P USD | 603K | 0.77% | +0.38% | Jul 2026 |
| iShares Russell 2000 Growth ETF | 594K | 0.76% | -0.38% | Oct 2026 |
| Fidelity Small Cap Growth | 474K | 0.60% | 0.00% | Aug 2026 |
| Vanguard Russell 2000 ETF | 454K | 0.58% | +1.13% | Sep 2026 |
| Fidelity Small Cap Discovery | 449K | 0.57% | +3.65% | Aug 2026 |
Top institutions holding CLDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Wellington Management Company LLP | 9.54M | 12.15% | +11.49% | Jun 2026 |
| BlackRock Inc | 7.00M | 8.92% | +30.40% | Jun 2026 |
| Kynam Capital Management, LP | 5.32M | 6.78% | -8.86% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 4.69M | 5.97% | +124.57% | Jun 2026 |
| State Street Corp | 3.90M | 4.97% | +39.09% | Jun 2026 |
| FMR Inc | 3.72M | 4.74% | -0.70% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.46M | 4.41% | +17.02% | Jun 2026 |
| Deep Track Capital, LP | 2.94M | 3.74% | +128.91% | Jun 2026 |
| Logos Global Management LP | 2.10M | 2.67% | +366.67% | Jun 2026 |
| Geode Capital Management, LLC | 2.02M | 2.57% | +19.79% | Jun 2026 |
| Eversept Partners, LP | 1.79M | 2.27% | -0.12% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.62M | 2.06% | +63.43% | Jun 2026 |
| Assenagon Asset Management SA | 1.58M | 2.01% | +976.53% | Jun 2026 |
| COMMODORE CAPITAL LP | 1.35M | 1.72% | -49.94% | Jun 2026 |
| Bellevue Group AG | 1.20M | 1.53% | 0.00% | Jun 2026 |
| Baker Bros Advisors LP | 1.18M | 1.51% | +77.74% | Jun 2026 |
| Millennium Management LLC | 1.17M | 1.49% | -6.60% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.15M | 1.46% | +6.94% | Sep 2026 |
| American Century Companies Inc | 1.04M | 1.33% | +21.73% | Jun 2026 |
| Eventide Asset Management, LLC | 1.04M | 1.32% | 0.00% | Jun 2026 |
Celldex Therapeutics Inc company profile
- Company name
- Celldex Therapeutics Inc
- Ticker
- CLDX.US
- Exchange
- USA Stocks
- Listed since
- Mar 10, 2008
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 198
- Fiscal year end
- December
- Address
- Perryville III Building, Hampton, NJ, United States, 08827
- Phone
- 908 200 7500
- Website
- celldex.com
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Celldex Therapeutics Inc management
10- Mr. Anthony S. Marucci M.B.A.Founder, President, CEO & Director · born 1962
- Dr. Tibor Keler Ph.D.Founder, Chief Scientific Officer & Executive VP · born 1959
- Mr. Sam Martin CPASenior VP, CFO, Secretary & Treasurer · born 1971
- Ms. Elizabeth CrowleyChief Product Development Officer & Senior VP · born 1972
- Dr. Margo Heath-Chiozzi M.D.Senior Vice President of Regulatory Affairs · born 1957
- Prof. Joseph P. Schlessinger Ph.D.Co-Founder & Member of Scientific Advisory Board · born 1945
- Ms. Sarah CavanaughSenior Vice President of Corporate Affairs & Administration · born 1975
- Mr. Freddy A. Jimenez Esq.Senior VP & General Counsel · born 1969
- Dr. Ronald A. Pepin Ph.D.Chief Business Officer & Senior VP · born 1956
- Dr. Diane C. Young M.D.Senior VP & Chief Medical Officer · born 1957